ABVX:EPA
Abivax SA
€82.00
arrow_downward
-1.80%(-1.50) 1D
Okt 5, 3:33:44 PM GMT+2 · EUR
search
Lahat ng simbolo
| Simbolo | Presyo | Palitan | % ng Pagbabago |
|---|
insights_autoBumubuo ng mga nangungunang insight para sa ABVX...
Buksan
€83.40
Mataas
€83.40
Mababa
€81.65
Mkt. cap
7.18B
Avg. na dami
155.90K
Dami
29.74K
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Buksan
€83.40
Mataas
€83.40
Mababa
€81.65
Mkt. cap
7.18B
Avg. na dami
155.90K
Dami
29.74K
Mataas nang 52-wk
€139.00
Mababa nang 52-wk
€60.45
EPS
-€5.20
Mga natitirang share
87.53M
Bilang ng mga empleyado
98
Mga balita at kwento
Mula sa mga source sa web at partner sa balita
Benzinga
·
7 oras ang nakalipas
Stock Market: Will S&P 500 Open Up or Down Today?
Reuters
·
5 oras ang nakalipas
Panmure Liberum forecasts S&P 500 falling to 5,000, warns bull run nearing end
Goldman Sachs
·
1 linggo ang nakalipas
Can AI Investment Drive S&P 500 Earnings Even Higher?
MarketWatch
·
3 araw ang nakalipas
The stock market is anything but normal right now — and these charts show it
Profile
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Tungkol sa Abivax SA
CEOMarc de Garidel | Hartmut J. Ehrlich
Mga Empleyado98
ItinatagDis 4, 2013
Headquarters-
Sektor-
Websiteabivax.com